NextGen - CRI

下一代 - CRI

基本信息

  • 批准号:
    10627010
  • 负责人:
  • 金额:
    $ 87.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-22 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

Next Generation T cell therapies for childhood cancers [NexTGen] Current treatments fail to cure many children with solid cancers. Recent advances in adult cancers such as checkpoint blockade and targeted small molecules have made little impact in childhood disease. Engineered T-cell therapies can achieve durable responses in refractory lymphoid cancers without long-term toxicity. These are precisely the characteristics required for new treatments for pediatric solid cancers. In contrast to hematologic malignancies, solid cancers are challenging due to a lack of targets, tumor heterogeneity, and hostile tumor microenvironment (TME). We posit that through advanced cellular engineering we can overcome these challenges. Our vision is that engineered T-cell therapy for childhood solid cancers will become routine within a decade. Our central hypothesis is that coupling of advanced cellular engineering along with progressive clinical development is the fastest route to developing effective T-cell therapies for pediatric solid tumors. In NexTGen, we combine detailed studies of primary tumors to discover new targets and understand how the TME subverts T- cell function. This, along with a closely coupled clinical development program will guide the progressive engineering of T-cells to result in transformative therapies. NexTGen is composed of 6 inter-connected work-packages (WPs) with work initially focused on pediatric sarcomas and brain tumors. AIMS: WP1: To identify suitable targets for engineered T-cells. WP2: To understand the TME in pediatric solid cancers. WP3: To develop receptors and other engineering components which target tumor cells and resist or modulate the TME. WP4: To evaluate the function of engineered T-cells developed in WP3. WP5: To translate approaches from WP4 and test them in clinical studies designed for maximal impact. Cancer Grand Challenges - Full Application - 2021 WP6: To promote data sharing across all WPs. METHODS: Target discovery (WP1) and TME studies (WP2) will utilize mass spectroscopy and chip cytometry respectively. Component engineering (WP3) will use protein engineering methods. To model engineered cell function, WP4 will mostly use intact tumor models such as immune PDXs. In WP5, clinical product generation will involve autologous closed system semi-automated manufacturing. WP6 uses standard and custom databases and data sharing platforms. USE OF RESULTS: Tumor target and TME data from WP1 and 2 will be uploaded to databases developed by WP6 for widespread distribution. Engineering components from WP3 and functional data from WP4 will be available for incorporation into therapeutic T-cell strategies by the entire community. Clinical study data from WP5 should lead to registration studies, improving cure rates and mitigation of long-term toxicity to realize our Vision.
儿童癌症的下一代T细胞疗法[NexTGen] 目前的治疗方法未能治愈许多患有实体癌的儿童。成人癌症的最新进展,如检查点阻断和靶向小分子,对儿童疾病的影响很小。工程化T细胞疗法可以在难治性淋巴癌中实现持久的反应,而没有长期毒性。这些正是儿科实体癌新疗法所需的特征。与血液恶性肿瘤相比,实体癌由于缺乏靶标、肿瘤异质性和不利的肿瘤微环境(TME)而具有挑战性。我们相信,通过先进的细胞工程,我们可以克服这些挑战。我们的愿景是,儿童实体癌的工程化T细胞疗法将在十年内成为常规疗法。我们的中心假设是,先进的细胞工程沿着渐进式临床开发的耦合是开发儿科实体瘤有效T细胞疗法的最快途径。在NexTGen中,我们联合收割机结合原发性肿瘤的详细研究,以发现新的靶点,并了解TME如何颠覆T细胞功能。这一点,沿着一个紧密结合的临床开发计划将指导T细胞的渐进工程,以产生变革性的治疗。NexTGen由6个相互连接的工作包(WP)组成,最初的工作重点是儿科肉瘤和脑肿瘤。WP 1:确定工程化T细胞的合适靶点。WP 2:了解儿科实体癌的TME。WP 3:开发靶向肿瘤细胞并抵抗或调节TME的受体和其他工程组件。WP 4:评估WP 3中开发的工程化T细胞的功能。WP 5:翻译WP 4的方法,并在旨在产生最大影响的临床研究中对其进行测试。Cancer Grand Challenges - Full Application - 2021 WP 6:促进所有WP之间的数据共享。方法:靶点发现(WP 1)和TME研究(WP 2)将分别利用质谱和芯片细胞术。组件工程(WP 3)将使用蛋白质工程方法。为了模拟工程细胞功能,WP 4将主要使用完整的肿瘤模型,如免疫PDX。在WP 5中,临床产品生成将涉及自体封闭系统半自动化制造。WP 6使用标准和自定义数据库以及数据共享平台。结果的使用:来自WP 1和2的肿瘤靶点和TME数据将上传至WP 6开发的数据库,以广泛分发。来自WP 3的工程组件和WP 4的功能数据将可用于整个社区的治疗性T细胞策略。WP 5的临床研究数据应导致注册研究,提高治愈率并减轻长期毒性,以实现我们的愿景。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Catherine M. Bollard其他文献

Reduced Intensity Allogeneic Stem Cell Transplantation Followed By Adoptive Cellular Immunotherapy with Donor Derived LMP Specific-CTLs in Patients with EBV Positive Refractory or Recurrent Hodgkin Lymphoma: A Lymphoma Cell Therapy Consortium (LCTC) Trial
  • DOI:
    10.1016/j.bbmt.2014.11.299
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jessica Hochberg;Renuka P. Miller;Patrick J. Hanley;Sarah McCormack;Lauren Harrison;Olga Militano;Phyllis Brand;Catherine M. Bollard;Mitchell S. Cairo
  • 通讯作者:
    Mitchell S. Cairo
CMVpp65-Specific T Cells Generated from Naïve T Cell Populations Recognize Atypical but Not Canonical Epitopes and May Be Protective In Vivo
  • DOI:
    10.1016/j.bbmt.2014.11.049
  • 发表时间:
    2015-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Patrick J. Hanley;Jan Melenhorst;Sarah Nikiforow;Phillip Scheinberg;Russell Cruz;Robert A. Krance;Kathryn Leung;Caridad Martinez;Helen E. Heslop;Cliona M. Rooney;A. John Barrett;Elizabeth J. Shpall;Catherine M. Bollard
  • 通讯作者:
    Catherine M. Bollard
A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)
  • DOI:
    10.1182/blood-2024-201138
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Robert Weinkove;Philip George;Robert Fyfe;Aine Hurley;Nathaniel Dasyam;Yasmin Nouri;Tess Ostapowicz;Stefan Mullins;Giulia Giunti;Brittany Lavender;Brigitta Mester;Catherine M. Bollard;Travis Perera;Hayden Jina;Alwyn D'Souza;Le Qin;David S. Ritchie;Chris M.A. Frampton;Rachel Perret;Peng Li
  • 通讯作者:
    Peng Li
Refined/Accelerated T Cell Therapies for the Treatment of EBV+ Lymphomas
  • DOI:
    10.1016/j.bbmt.2013.12.206
  • 发表时间:
    2014-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Serena Kimi Perna;Minthran Ngo;Natalia Lapteva;Jun Ando;Lisa Rollins;Oumar Diouf;Ann M. Leen;Juan F. Vera;Vicky Torrano;Adrian P. Gee;Stephen Gottschalk;Carlos A. Ramos;Catherine M. Bollard;Helen E. Heslop;Cliona M. Rooney
  • 通讯作者:
    Cliona M. Rooney
Ultra-Low Dose IL-2 Expands Natural Regulatory T Cells and CD56bright NK Cells in Patients and Healthy Donors and Is Associated with Clinical Improvement in Chronic Graft Versus Host Disease
  • DOI:
    10.1016/j.bbmt.2012.11.098
  • 发表时间:
    2013-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sawa Ito;Nancy Hensel;Minoo Battiwalla;Jan Melenhorst;Pawel Muranski;Samantha Miner;Kazushi Tanimoto;Fang Yin;Keyvan Keyvanfar;Libby Koklanaris;Jeanine Superata;Jan Haggerty;Catherine M. Bollard;A. John Barrett
  • 通讯作者:
    A. John Barrett

Catherine M. Bollard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Catherine M. Bollard', 18)}}的其他基金

NextGen - CRI
下一代 - CRI
  • 批准号:
    10845777
  • 财政年份:
    2022
  • 资助金额:
    $ 87.12万
  • 项目类别:
Cancer Immunotherapy Winter School (CIWS)
癌症免疫治疗冬季学校(CIWS)
  • 批准号:
    10391811
  • 财政年份:
    2022
  • 资助金额:
    $ 87.12万
  • 项目类别:
Antigen Specific T Cells
抗原特异性 T 细胞
  • 批准号:
    10197003
  • 财政年份:
    2019
  • 资助金额:
    $ 87.12万
  • 项目类别:
Antigen Specific T Cells
抗原特异性 T 细胞
  • 批准号:
    10671624
  • 财政年份:
    2019
  • 资助金额:
    $ 87.12万
  • 项目类别:
Enhancing cell therapy for brain tumors
增强脑肿瘤的细胞治疗
  • 批准号:
    9788348
  • 财政年份:
    2018
  • 资助金额:
    $ 87.12万
  • 项目类别:
Enhancing cell therapy for brain tumors
增强脑肿瘤的细胞治疗
  • 批准号:
    10477394
  • 财政年份:
    2018
  • 资助金额:
    $ 87.12万
  • 项目类别:
Enhancing cell therapy for brain tumors
增强脑肿瘤的细胞治疗
  • 批准号:
    10246936
  • 财政年份:
    2018
  • 资助金额:
    $ 87.12万
  • 项目类别:
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection
HIV 特异性体外扩增 T 细胞疗法 (HXTC) 可消除持续性 HIV 感染的潜在储库
  • 批准号:
    9889986
  • 财政年份:
    2016
  • 资助金额:
    $ 87.12万
  • 项目类别:
Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National
国家儿童医院儿科血液学和输血医学多学科研究培训奖 (PHTMMRT) 的理由
  • 批准号:
    10360585
  • 财政年份:
    2012
  • 资助金额:
    $ 87.12万
  • 项目类别:
Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National
国家儿童医院儿科血液学和输血医学多学科研究培训奖 (PHTMMRT) 的理由
  • 批准号:
    9417175
  • 财政年份:
    2012
  • 资助金额:
    $ 87.12万
  • 项目类别:

相似国自然基金

车载中央计算平台软件框架及泊车功能研发与产业化应用
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
低空飞行器及其空域的设计与监管平台软件
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于金刚石高效散热封装的高功率高压GaN器件研发与产业化
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
新能源智能汽车高性能精密零部件装备研制与产业化
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
高效智能化超低风速风电机组关键技术及装备研制
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
绿氢制储加注关键技术与装备研发
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
复杂电子产品超精密加工及检测关键技术研究与应用
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
抗消化性溃疡新药研发
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于合成生物学的动物底盘品种优化及中试应用研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
1.1 类中药创新药“鱼酱排毒合剂”开发
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目

相似海外基金

EAGER: Integrating Pathological Image and Biomedical Text Data for Clinical Outcome Prediction
EAGER:整合病理图像和生物医学文本数据进行临床结果预测
  • 批准号:
    2412195
  • 财政年份:
    2024
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Standard Grant
Development of social attention indicators of emerging technologies and science policies with network analysis and text mining
利用网络分析和文本挖掘开发新兴技术和科学政策的社会关注指标
  • 批准号:
    24K16438
  • 财政年份:
    2024
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
'And many a strange adventure came my way in that time': Adaptation of the 13th c. French text 'The Quest of the Holy Grail' in 15th c. Ireland.
“在那段时间里,我经历了许多奇怪的冒险”:改编自 13 世纪。
  • 批准号:
    2506854
  • 财政年份:
    2024
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Studentship
Conference on text production and comprehension by human and artificial intelligence
人类和人工智能文本生成和理解会议
  • 批准号:
    2422404
  • 财政年份:
    2024
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Standard Grant
自動音声認識を利用したbilingual speech-to-textシステム構築と授業分析への応用
自动语音识别双语语音转文本系统的构建及其在课程分析中的应用
  • 批准号:
    24K04125
  • 财政年份:
    2024
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Cyber Graph-to-Text: AI automation for Threat Intelligence, made accessible to all
网络图文转换:威胁情报的人工智能自动化,可供所有人使用
  • 批准号:
    10052569
  • 财政年份:
    2023
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Investment Accelerator
Applied research towards practical use of Devanagari OCR and utilization of text database
天城文 OCR 实用化和文本数据库利用的应用研究
  • 批准号:
    23H00564
  • 财政年份:
    2023
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Develpment of a Method of Text Encoding for Japanese Historical Texts Accoding to Methdological Commons
根据方法论共同点开发日本历史文本文本编码方法
  • 批准号:
    23H03696
  • 财政年份:
    2023
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Tradition and the Text/Image: Ed Ruscha's Word Paintings and the Multimodal Legacies of American Modernism
传统与文本/图像:艾德·拉斯查的文字绘画与美国现代主义的多模态遗产
  • 批准号:
    2875687
  • 财政年份:
    2023
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Studentship
Understanding Processes of Neighborhood Change using Property Text Analytics
使用属性文本分析了解社区变化的过程
  • 批准号:
    2314726
  • 财政年份:
    2023
  • 资助金额:
    $ 87.12万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了